Novo Nordisk A/s

Amgen Inc.

Mette Dahl Andersen

Susanne Nedergaard Grell

Henrik Sune Andersen

Kristian Kjaergaard

Soeren Padkjaer

Birgitte Friedrichsen

Jens Buchardt

Peder Lisby Noerby

Albrecht Gruhler

Jesper Kastrup

Katarina Haakansson

Lars Hornum

Dorrit Baunsgaard

Richard Jeffrey Armitage

Jens Breinholt

Lars Christian Petersen

Ida Hilden

Vibeke Westphal Stennicke

Anette Henriksen

Rutilio Clark

Jes Thorn Clausen

Charlotte Wiberg

Marco Colonna

Rune Salbo

Jais Rose Bjelke

Axel Bouchon

Thomas Egebjerg

Jeff Dantzler

The current invention relates to procoagulant fusion proteins, polynucleotides that encode said fusion proteins and cells that expresses said fusion proteins. Furthermore, the current invention relates to fusion proteins for use as a medicament. Individuals that have a coagulopathy, such as haemophilia A and B with or without inhibitors, may be treated with fusions proteins of the current invention.

Targeting tissue factor to activated platelets

Provided are compositions and methods relating to human CD30L antigen binding proteins. Compositions described herein include: human CD30L antigen binding proteins, polynucleotides encoding human CD30L antigen binding proteins, vectors comprising these polynucleotides, host cells, and pharmaceutical compositions. Methods of making and using each of these compositions are also provided.

Human CD30 ligand antigen binding proteins

The present disclosure relates to treatment of inflammatory diseases. In particular, the present disclosure relates to antagonistic DR3 ligands useful for treating inflammatory diseases.

Antagonistic DR3 ligands

The present invention relates to treatment of inflammatory diseases. In particular, the present invention relates to antagonistic DR3 ligands useful for treating inflammatory diseases.

Novel activating receptors of the lg super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-&#x3b2;. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders.

Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof

Growing community of inventors

Vaerloese, Denmark

Mette Dahl Andersen